# Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors

> **NCT05145907** · PHASE2 · UNKNOWN · sponsor: **TJ Biopharma Co., Ltd.** · enrollment: 133 (estimated)

## Conditions studied

- Triple-negative Breast Cancer
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** TJ107 +Pembrolizumab

## Key facts

- **NCT ID:** NCT05145907
- **Lead sponsor:** TJ Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-22
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 133 (ESTIMATED)
- **Last updated:** 2024-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05145907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05145907, "Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05145907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*